Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Sofie Bjerrum

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
ERJ Open Research|March 18, 2026
Cumulative corticosteroid burden over 25 years in patients initiating biologic therapy for severe asthma: a nationwide cohort studyGalathea Berner, Marianne Baastrup Soendergaard, Susanne Hansen, et al.
Chest|November 4, 2023
Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic TherapiesSusanne Hansen, Marianne Baastrup Søndergaard, Anna von Bülow, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 5, 2026
Five-year inhaled, systemic and total corticosteroid exposure reduction during anti-Interleukin-5/Rα treatment for severe asthmaKjell Erik Julius Håkansson, Susanne Hansen, Marianne Baastrup Soendergaard, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 13, 2025
Tezepelumab in Real-Life Practice: Characteristics of Patients Commenced and Efficacy in a Nationwide, Danish Cohort of Patients With Severe AsthmaMarianne Baastrup Soendergaard, Kjell Erik Julius Haakansson, Susanne Hansen, et al.
Lung|March 12, 2025
Supratherapeutic Inhaled Corticosteroid Use in Patients Initiating on Biologic Therapies for Severe Asthma: A Nationwide Cohort StudyFrederikke Hjortdahl, Marianne Baastrup Soendergaard, Susanne Hansen, et al.
The European Respiratory Journal|January 9, 2025
Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthmaMarianne Baastrup Soendergaard, Frederikke Hjortdahl, Susanne Hansen, et al.
ERJ Open Research|October 6, 2022
Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma RegisterMarianne Baastrup Soendergaard, Susanne Hansen, Anne-Sofie Bjerrum, et al.
Allergy|December 14, 2024
Early Reduction of FeNO on Anti-IL5 Biologics Is Associated With Clinical Remission of Severe AsthmaMarianne Baastrup Soendergaard, Susanne Hansen, Kjell Erik Julius Håkansson, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|July 15, 2025
Biologic Prescription Patterns and Biomarker Determinants of First-Line Dupilumab in Danish Adult Patients With Severe Asthma and Comorbid Atopic DermatitisMarianne Baastrup Soendergaard, Kjell Erik Julius Håkansson, Susanne Hansen, et al.
Respiratory Medicine|June 13, 2025
Clinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma RegisterSusanne Hansen, Kjell Erik Julius Håkansson, Marianne Baastrup Soendergaard, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
ERJ Open Research|March 18, 2026
Cumulative corticosteroid burden over 25 years in patients initiating biologic therapy for severe asthma: a nationwide cohort studyGalathea Berner, Marianne Baastrup Soendergaard, Susanne Hansen, et al.
Chest|November 4, 2023
Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic TherapiesSusanne Hansen, Marianne Baastrup Søndergaard, Anna von Bülow, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|April 5, 2026
Five-year inhaled, systemic and total corticosteroid exposure reduction during anti-Interleukin-5/Rα treatment for severe asthmaKjell Erik Julius Håkansson, Susanne Hansen, Marianne Baastrup Soendergaard, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 13, 2025
Tezepelumab in Real-Life Practice: Characteristics of Patients Commenced and Efficacy in a Nationwide, Danish Cohort of Patients With Severe AsthmaMarianne Baastrup Soendergaard, Kjell Erik Julius Haakansson, Susanne Hansen, et al.
Lung|March 12, 2025
Supratherapeutic Inhaled Corticosteroid Use in Patients Initiating on Biologic Therapies for Severe Asthma: A Nationwide Cohort StudyFrederikke Hjortdahl, Marianne Baastrup Soendergaard, Susanne Hansen, et al.
The European Respiratory Journal|January 9, 2025
Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthmaMarianne Baastrup Soendergaard, Frederikke Hjortdahl, Susanne Hansen, et al.
ERJ Open Research|October 6, 2022
Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma RegisterMarianne Baastrup Soendergaard, Susanne Hansen, Anne-Sofie Bjerrum, et al.
Allergy|December 14, 2024
Early Reduction of FeNO on Anti-IL5 Biologics Is Associated With Clinical Remission of Severe AsthmaMarianne Baastrup Soendergaard, Susanne Hansen, Kjell Erik Julius Håkansson, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|July 15, 2025
Biologic Prescription Patterns and Biomarker Determinants of First-Line Dupilumab in Danish Adult Patients With Severe Asthma and Comorbid Atopic DermatitisMarianne Baastrup Soendergaard, Kjell Erik Julius Håkansson, Susanne Hansen, et al.
Respiratory Medicine|June 13, 2025
Clinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma RegisterSusanne Hansen, Kjell Erik Julius Håkansson, Marianne Baastrup Soendergaard, et al.
Pageof 3